Clinical bottom line
Chemotherapy-induced peripheral neuropathy (CIPN) is a common, often debilitating complication in palliative care patients receiving neurotoxic chemotherapy. Current evidence supports a multimodal approach to symptom management, including pharmacologic options such as methadone and nonpharmacologic interventions like scrambler therapy and physical therapy. While no definitive cure exists, integrating these modalities may improve pain control and functional outcomes. Emerging therapies warrant further validation before routine adoption.
What the evidence shows
CIPN manifests as sensory, motor, and autonomic symptoms that significantly impair quality of life in patients with advanced cancer (Paice et al., 2017). The pathophysiology involves chemotherapy-induced damage to peripheral nerves, with limited spontaneous recovery in many cases.
Pharmacologic management remains challenging. Methadone, a long-acting opioid with NMDA receptor antagonism, has shown promise in retrospective analyses for CIPN-related pain refractory to conventional opioids (Boen et al., 2024). This suggests methadone may provide superior analgesia for neuropathic components, but prospective trials are lacking.
Nonpharmacologic interventions are gaining attention. Scrambler therapy, a form of transcutaneous neurostimulation, demonstrated symptomatic relief in a recent case report, suggesting potential benefit in CIPN pain modulation (Wang et al., 2025). Physical therapy may play a role in both prevention and management by improving nerve function and reducing disability, although high-quality evidence remains limited (Kumar SenthilParamasivam et al., 2013).
Cannabis-based therapies and mindfulness approaches have been proposed for symptom control, with some supportive data in broader neuropathic pain contexts, but specific CIPN evidence is preliminary (Teoh et al., 2018). Spinal cord stimulation is an emerging option for refractory cancer pain, including neuropathic components, but its role in CIPN specifically requires further study (Odonkor et al., 2026).
Caveats and uncertainty
The evidence base for CIPN management in palliative care is constrained by small sample sizes, heterogeneous patient populations, and a paucity of randomized controlled trials. Methadone’s retrospective data require cautious interpretation due to potential confounding and selection bias. Scrambler therapy evidence is largely anecdotal or from small case series, limiting generalizability.
Physical therapy protocols vary widely, and optimal timing, intensity, and modalities for CIPN prevention or treatment remain undefined. Cannabis and mindfulness interventions lack robust CIPN-specific trials, so their efficacy and safety profiles in this population are uncertain.
Moreover, CIPN symptoms can overlap with other neuropathic or musculoskeletal conditions, complicating diagnosis and management. Individual patient factors such as comorbidities, concurrent medications, and prognosis must guide therapeutic decisions.
How this may change practice
Clinicians should adopt a comprehensive, individualized approach to CIPN symptom management in palliative care, incorporating both pharmacologic and nonpharmacologic strategies. Methadone may be considered for patients with refractory neuropathic pain, with careful monitoring and specialist consultation.
Referral to physical therapy should be encouraged to optimize functional status and potentially mitigate neuropathy progression. Emerging modalities like scrambler therapy could be offered in specialized centers or clinical trials, pending further validation.
Education on realistic expectations and symptom self-management remains essential. Multidisciplinary collaboration is critical to balance symptom relief with quality of life, especially given the limited curative options for CIPN.